Join our daily newsletter At The Bell to receive exclusive market insights
- G Medical Innovations (GMV) has completed the required trials for National Medical Products Administrations tick of approval to use Prizma device in China
- The technology allows customers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs
- G Medical trialled 208 patients at three of its partner hospitals in China
- Results from the patients are currently being assessed by the company and will be lodged by the end of April
- The company is confident it will receive the approval
- G Medical is up 22.22 per cent on the market this morning, selling shares at 11¢ each
G Medical Innovations (GMV) has completed the required trials for National Medical Products Administrations (NMPA) tick of approval.
NMPA, formally the China Food and Drug Administration, will determine if G Medical’s Prizma device can be used in the People’s Republic of China.
Prizma Medical Smartphone Case is one of the two key products developed by the company and is aimed at everyday consumers focused on their medical health and wellbeing.
The technology allows customers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs. It also stores the medical data and shares it with healthcare professionals and family members.
G Medical trialled 208 patients at three of its partner hospitals in China.
The trials measured patients electrocardiography, blood-oxygen saturation and body temperature using the Prizma device, compared to the gold standard hospital diagnostic equipment.
Results from the patients are currently being assessed by the company and will be lodged by the end of April. The company is confident it will receive the NMPA clearance.
CEO Yacov Geva says the completion of these trials is a major milestone for G Medical and is an important step for the entry into the large Chinese market.
“The company will shortly lodge the required documentation to the regulator and we are confident that NMPA approval will be received towards the middle of the year,” Yacov said.
“Following this, the provisions for our device sales and services are expected to be able to materialise quickly via our existing established in-country partners, as well as to allow for additional partnerships to be explored,” he added.
G Medical is up 22.22 per cent on the market this morning, selling shares at 11¢ per share at 11:39 am AEDT.
